| ZOE Stock | | | EUR 164.56 3.70 2.20% |
President
Mr. Glenn David serves as Chief Financial Officer and Executive Vice President of the Company. Mr. David has played a key role in leading the financial operations for Zoetis since its initial public offering in 2013. He served as our Senior Vice President of Finance Operations from 2013 to 2016 and as acting Chief Financial Officer from April 2014 through August 2014 since 2016.
| Age | 51 |
| Tenure | 8 years |
| Phone | 973 822 7000 |
| Web | https://www.zoetis.com |
David joined Pfizer in 1999 and held various financial roles, including Vice President of Global Finance for Pfizer Animal Health, our predecessor company, and Vice President of Finance for the U.S. Primary Care franchise.
Zoetis Management Efficiency
The company has return on total asset
(ROA) of
0.1273 % which means that it generated a profit of $0.1273 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.4719 %, meaning that it generated $0.4719 on every $100 dollars invested by stockholders. Zoetis' management efficiency ratios could be used to measure how well Zoetis manages its routine affairs as well as how well it operates its assets and liabilities.
Zoetis Inc has accumulated 6.55
B in total debt with debt to equity ratio
(D/E) of 285.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Zoetis Inc has a current ratio of 3.97, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Zoetis until it has trouble settling it off, either with new capital or with free cash flow. So, Zoetis' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Zoetis Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Zoetis to invest in growth at high rates of return. When we think about Zoetis' use of debt, we should always consider it together with cash and equity.
Similar Executives
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. ZOETIS INC operates under Drug Manufacturers - Specialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 10000 people. Zoetis Inc (ZOE) is traded on Frankfurt Exchange in Germany and employs 13,800 people.
Management Performance
Zoetis Inc Leadership Team
Elected by the shareholders, the Zoetis' board of directors comprises two types of representatives: Zoetis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zoetis. The board's role is to monitor Zoetis' management team and ensure that shareholders' interests are well served. Zoetis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zoetis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven Frank, VP Relations | |
| Kristin Peck, Executive Vice President and Presidentident - U.S. Operations | |
| Wafaa Mamilli, Chief EVP | |
| William Price, VP Officer | |
| Roxanne Lagano, Chief Human Resource Officer, Executive Vice President | |
| Jeannette Astorga, Exec Officer | |
| Robert Polzer, Ex RD | |
| Glenn David, CFO, Executive Vice President | |
| Heidi Chen, Executive Vice President General Counsel, Corporate Secretary | |
| Wetteny Joseph, Ex CFO | |
Zoetis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zoetis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Zoetis Stock
When determining whether Zoetis Inc is a strong investment it is important to analyze Zoetis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zoetis'
future performance.
For an informed investment choice regarding Zoetis Stock, refer to the following important reports: Check out
Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zoetis Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
You can also try the
Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Please note, there is a significant difference between Zoetis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zoetis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zoetis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.